Ocugen, Inc.

200 articles with Ocugen, Inc.

• Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

  3/27/2023

  Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the FDA approved enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial.

• Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference

  3/7/2023

  Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 at the Ritz Carlton, Laguna Niguel in Dana Point, California.

• Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer

  3/6/2023

  Ocugen, Inc. today announced the appointment of Quan A. Vu to Chief Financial Officer & Chief Business Officer.

• Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema

  2/27/2023

  Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) today announced that it has submitted an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of OCU200, a fusion protein with a distinct mechanism of action (MOA), for the treatment of diabetic macular edema (DME).

• Ocugen to Present at Retinal Vascular Disease Drug Development Summit - February 17, 2023

  2/17/2023

  Ocugen, Inc. announced that the Company’s Chief Scientific Officer, Arun Upadhyay, Ph.D., will participate in the Retinal Vascular Disease Drug Development Summit at the Hilton Boston Logan Airport in Boston, Mass. from February 21-23, 2023.

• Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results

  2/15/2023

  Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2022 financial results and provide a business update at 8:30 a.m. ET on Tuesday, February 28, 2023.

• Ocugen Appoints Quan A. Vu as Chief Business Officer

  2/1/2023

  Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Quan A. Vu as Chief Business Officer, responsible for securing new business development partnerships, including in/out licensing opportunities, across the Company’s pipeline.

• Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference

  1/31/2023

  Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City.

• Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

  1/9/2023

  Ocugen, Inc. (Ocugen) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced positive results from the Phase 2/3, observer-blind, immuno-bridging and broadening study of its COVID-19 vaccine candidate, COVAXIN™.

• 

  NeoCart's Revival Continues as FDA Approves Ocugen's Phase III Trial Design (Updated)

  12/16/2022

  Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.

• Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®Important next step for Ocugen’s regenerative cell therapy in orthopedics since announcing pipeline expansion in May 2022

  12/16/2022

  Ocugen, Inc. today announced that the U.S. Food & Drug Administration (FDA) agreed to Ocugen’s proposed control and overall design for the Phase 3 study of NeoCart ®, a regenerative cell therapy for the repair of full-thickness lesions of the knee cartilage in adults.

• Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital AmaurosisU.S. Food & Drug Administration (FDA) acknowledges the potential of OCU400 to treat rare inherited retinal diseases

  12/15/2022

  Ocugen, Inc. announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 —for the treatment of retinitis pigmentosa and Leber congenital amaurosis.

• Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

  12/7/2022

  Ocugen, Inc. today announced that the Data Safety and Monitoring Board (DSMB) for the OCU400 clinical trial recently convened and established high dose as the maximum tolerable dose (MTD) in the dose-escalation phase of the study.

• Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit

  11/28/2022

  Ocugen, Inc. today announced that the Company’s Chief Scientific Officer, Arun Upadhyay, Ph.D., will participate in the 3rd Annual Dry AMD Therapeutics Summit at the Revere Hotel in Boston, Mass. from November 30-December 2, 2022.

• Ocugen Provides Business Update & Third Quarter 2022 Financial Results

  11/8/2022

  Ocugen, Inc. today reported financial results for the quarter ended September 30, 2022, and provided a general business update.

• Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results

  10/27/2022

  Ocugen, Inc. today announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2022 financial results and provide a business update at 8:30 a.m. ET on Tuesday, November 8, 2022.

• Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022

  10/19/2022

  Ocugen, Inc. today announced that it will host an in-person Research & Development (R&D) Day on Tuesday, November 1, 2022.

• Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

  10/12/2022

  Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Independent Data and Safety Monitoring Board (DSMB) for the OCU400 Phase 1/2 clinical trial completed a review of safety data for subjects enrolled in Cohort 2 and recommends proceeding to enroll subjects in Cohort 3.

• Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences

  10/6/2022

  Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month.

• Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference

  9/29/2022

  Ocugen, Inc. today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will participate in an in-person fireside chat at the Chardan 6th Annual Genetic Medicines Conference being held October 3-4, 2022 in New York, NY.